Healing the injured vessel wall using microRNA-facilitated gene delivery

Journal of Clinical Investigation

Volumn 124, Issue 9, 2014, Pages 3694-3697

  Feinberg, Mark W ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MICRORNA; MIRN126 MICRORNA, HUMAN;

ARTERY INTIMA PROLIFERATION; BLOOD VESSEL INJURY; CELL PROLIFERATION; ENDOTHELIUM CELL; GENE TARGETING; HEALING; HUMAN; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; ANIMAL; CORONARY RESTENOSIS; GENETICS; MALE; PHYSIOLOGY;

ANIMALS; CORONARY RESTENOSIS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; ENDOTHELIAL CELLS; HUMANS; MALE; MICRORNAS;

EID: 84907011124     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI77509     Document Type: Review

References (32)

1. Inoue T, Croce K, Morooka T, Sakuma M, Node K, Simon DI. Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv. 2011;4(10):1057-1066.
2. Lafont A, Guzman LA, Whitlow PL, Goormastic M, Cornhill JF, Chisolm GM. Restenosis after experimental angioplasty. Intimal, medial, and adventitial changes associated with constrictive remodeling. Circ Res. 1995;76(6):996-1002.
3. Fischman DL, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994;331(8):496-501.
4. Macaya C, et al. Continued benefit of coronary stenting versus balloon angioplasty: one-year clinical follow-up of Benestent trial. Benestent Study Group. J Am Coll Cardiol. 1996;27(2):255-261.
5. Stettler C, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370(9591):937-948.
6. Stefanini GG, Holmes DR, Holmes DR Jr. Drug-eluting coronary-artery stents. N Engl J Med. 2013;368(3):254-265.
7. Luscher TF, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation. 2007;115(8):1051-1058.
8. Garg P, Mauri L. The conundrum of late and very late stent thrombosis following drug-eluting stent implantation. Curr Opin Cardiol. 2007;22(6):565-571.
9. Kotani J, et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol. 2006;47(10):2108-2111.
10. Joner M, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48(1):193-202.
11. Lagerqvist B, et al. Stent thrombosis in Sweden: a report from the Swedish Coronary Angiography and Angioplasty Registry. Circ Cardiovasc Interv. 2009;2(5):401-408.
12. McFadden EP, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364(9444):1519-1521.
13. Mauri L, et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J. 2010;160(6):1035-1041.
14. Go AS, et al. Heart disease and stroke statistics - 2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28-e292.
15. Palmerini T, et al. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2014;63(4):299-307.
16. Wara AK, et al. Bone marrow-derived Kruppellike factor 10 controls reendothelialization in response to arterial injury. Arterioscler Thromb Vasc Biol. 2013;33(7):1552-1560.
17. van Beusekom HM, Ertas G, Sorop O, Serruys PW, van der Giessen WJ. The Genous endothelial progenitor cell capture stent accelerates stent re-endothelialization but does not affect intimal hyperplasia in porcine coronary arteries. Catheter Cardiovasc Interv. 2012;79(2):231-242.
18. Beijk MA, et al. Genous endothelial progenitor cell capturing stent vs. the Taxus Liberte stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized, single-centre, pilot study. Eur Heart J. 2010;31(9):1055-1064.
19. Nabel EG, Plautz G, Boyce FM, Stanley JC, Nabel GJ. Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science. 1989;244(4910):1342-1344.
20. Tanner FC, et al. Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation. Circulation. 2000;101(17):2022-2025.
21. Santulli G, et al. A selective microRNA-based strategy inhibits restenosis while preserving endothelial function. J Clin Invest. 2014;124(9):4102-4114.
22. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215-233.
23. Sun X, Belkin N, Feinberg MW. Endothelial microRNAs and atherosclerosis. Curr Atheroscler Rep. 2013;15(12):372.
24. Olson EN. MicroRNAs as Therapeutic Targets and Biomarkers of Cardiovascular Disease. Sci Transl Med. 2014;6(239):239ps233.
25. Wang S, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 2008;15(2):261-271.
26. Sims FH. A comparison of structural features of the walls of coronary arteries from 10 different species. Pathology. 1989;21(2):115-124.
27. Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug-eluting stents: still important, still much to learn. J Am Coll Cardiol. 2004;44(7):1373-1385.
28. Zhou J, et al. Regulation of vascular smooth muscle cell turnover by endothelial cell-secreted microRNA-126: role of shear stress. Circ Res. 2013;113(1):40-51.
29. Moss SC, Lightell DJ, Lightell DJ Jr, Marx SO, Marks AR, Woods TC. Rapamycin regulates endothelial cell migration through regulation of the cyclin-dependent kinase inhibitor p27Kip1. J Biol Chem. 2010;285(16):11991-11997.
30. Schober A, et al. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat Med. 2014;20(4):368-376.
31. Kelly EJ, Hadac EM, Greiner S, Russell SJ. Engineering microRNA responsiveness to decrease virus pathogenicity. Nat Med. 2008;14(11):1278-1283.
32. Brown BD, Naldini L. Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat Rev Genet. 2009;10(8):578-585.